Assessment of antibody isotype profiles following vaccination, CHMI and natural exposure.

<p>Isotype profiles of serum antibody responses were assessed by ELISA. (A) Individual and median anti-MSP119 serum antibody isotype responses are shown for MSP1-only vaccinees at the peak after the MVA MSP1 boost (“Vaccine”, <i>n</i> = 12) and at dC+35 following CHMI (“Vaccine+CHMI”, <i>n</i> = 11) <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0107903#pone.0107903-Sheehy3" target="_blank">[21]</a>; at dC+35 for 18 infectivity control volunteers from three separate CHMI studies <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0107903#pone.0107903-Sheehy3" target="_blank">[21]</a>, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0107903#pone.0107903-Ewer1" target="_blank">[22]</a>; and from 20 naturally-exposed immune adults from Kilifi, Kenya. (B) Individual and median anti-AMA1 serum antibody isotype responses are shown for AMA1-only vaccinees at the peak after the MVA AMA1 boost (<i>n</i> = 9) and at dC+35 following CHMI (<i>n</i> = 9) <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0107903#pone.0107903-Sheehy3" target="_blank">[21]</a>; and for infectivity control volunteers and naturally-exposed immune adults from Kilifi, Kenya as in panel A.